|The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision-making in Phase I trials of investigational therapies, confident that the IBs are technically valid, that a measured change in the IB faithfully reflects the desired change in the underlying tumour pathology, and that the IBs can be readily deployed in multiple cancer centres in a robust, consistent, ethical, and cost-effective way acceptable to patients.2.(10% of resource, WP6) includes a portfolio of innovative approaches to devise, evaluate and introduce IBs of invasion and metastasis.The IBs of tumour cell proliferation and necrosis will be developed respectively from FLT PET and ADC MRI respectively. Initial apoptosis plans focus on ICMT11 PET, possibly with other IBs introduced later. The project will be delivered using a portfolio of animal (WP2), human (WP3), image analysis (WP4) and regulatory (WP5) work. The project will be coordinated and the interdependent workpackages integrated in WP1. These WPs will deliver image acquisition and analysis protocols which are technically valid, standardised and suitable for multicentre use. We will evaluate reproducibility, effects of intervention, timing, dose-response, and imaging-histopathology correlation in animals and patients. The project is timely, and highly likely to deliver IBs which will markedly improve drug development, and benefit cancer patients in Europe and globally. The managing entity (EORTC) is already world-leading in the qualification of IBs, and the consortium includes in the academic and EFPIA partners some of the world's most productive and innovative physicians and scientists in cancer imaging.